Search

Displaying results 1611 - 1620 of 10000 in total
  1. Drug

    Selinexor

    go.drugbank.com/drugs/DB11942
    ApprovedInvestigational

    [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at … [L10145] The FDA approved Selinexor in June 2019.

  2. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication.

  3. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.

  4. Drug

    Scarlet red

    go.drugbank.com/drugs/DB19136
    ApprovedWithdrawn

    Scarlet red is under investigation in clinical trial NCT00591916 (New Treatment for Donor Sites).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.

  7. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.

  8. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. … Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.

  9. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … [L48116] When administered alongside [filgrastim], another agent used to aid in stem cell collection, motixafortide enabled the collection of an adequate number of stem cells in ~92% of patients within

  10. Drug

    Propylparaben

    go.drugbank.com/drugs/DB14177
    Approved

    Propylparaben is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: n-propyl paraben, n-Propyl 4-hydroxybenzoate